CALLABLE EXPRESS DEFENDER VONCERT - BIONTECH ADR/ELI LILLY & CO/NOVO-NORDISK B/PFIZER INC CALLABLE EXPRESS DEFENDER VONCERT - BIONTECH ADR/ELI LILLY & CO/NOVO-NORDISK B/PFIZER INC Stock
Certificat
F46923
DE000VD383X3
| Market Closed - Borsa Italiana 11:44:59 2024-05-17 EDT | ||
| 101.8 EUR | +0.89% |
|
| Current month | +0.74% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 101.8 | -0.20% |
| 24-05-16 | 102 | -0.10% |
| 24-05-15 | 102 | +0.25% |
| 24-05-14 | 101.8 | -0.05% |
| 24-05-13 | 101.8 | +0.05% |
Real-time Borsa Italiana
Last update May 17, 2024 at 11:44 am
More quotesStatic data
| Product type | Reverse Convertibles |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| F46923 | |
| ISIN | DE000VD383X3 |
| Date issued | 2024-04-18 |
| Strike | 745.9 $ |
| Maturity | 2026-04-16 (697 Days) |
| Parity | 1 : 1 |
| Emission price | 100 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 102 € |
|---|---|
| Lowest since issue | 99.7 € |
| Spread | 1.1 € |
| Spread % | 1.08% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
770
USD
Average target price
850.4
USD
Spread / Average Target
+10.44%
- Stock Market
- Certificates
- F46923 Certificat
